FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to endocrinology, and concerns treating neurovascular complications of diabetes. That is ensured by the additional administration of Mildronat in dosage 1000 mg a day with underlying baseline therapy consisting in the introduction of antihyperglycemic drugs, ACE inhibitors and antioxidants. Mildronat is introduced intravenously 30 minutes and orally 60 minutes prior to the introduction of the disease-modifying agents.
EFFECT: medication regiment ensures an effective treatment of diabetic polyneuropathy due to correction of hemodynamic disorders, blood rheology and improved conduction of excitement in motor and sensor nerve fibres.
1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATING DIABETIC POLYNEUROPATHY | 2004 |
|
RU2262928C1 |
| METHOD FOR TREATING PATIENTS AT CHRONIC GLOMERULONEPHRITIS | 2004 |
|
RU2262337C1 |
| METHOD OF COMPLEX IMMUNOMODULATING TREATMENT OF PATIENTS WITH CHRONIC HEART FAILURE | 2010 |
|
RU2428980C1 |
| APPLICATION OF 2-ETHYL-6-METHYL-3-OXYPYRIDINE SUCCINATE FOR TREATMENT OF NEPHRITIS AND NEPHROPATHY | 2004 |
|
RU2290930C2 |
| METHOD OF TREATING PATIENTS WITH CHRONIC VIRAL HEPATITIS TYPE C, GENOTYPE 3a | 2009 |
|
RU2400229C1 |
| METHOD OF 2ND TYPE DIABETES TREATMENT COMPLICATED BY POLYNEUROPATHY | 2007 |
|
RU2350324C1 |
| METHOD OF TREATMENT OF PATIENTS WITH DIABETES MELLITUS | 1996 |
|
RU2134109C1 |
| METHOD OF PREDICTING EFFICIENCY OF TREATMENT OF PATIENTS WITH CHRONIC BRAIN ISCHEMIA AND TYPE 2 DIABETES MELLITUS WITH PHARMACOLOGIC PREPARATION MILDRONAT | 2010 |
|
RU2427367C1 |
| METHOD FOR MONITORING INDIVIDUALS WITH RISK OF EARLY ATHEROSCLEROSIS AND SUFFERING FROM TYPE 2 DIABETES MELLITUS | 2013 |
|
RU2533836C1 |
| BRONCHIAL ASTHMA TREATMENT MODE | 2008 |
|
RU2360698C1 |
